• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Use of remdesivir in the presence of elevated LFTs for the treatment of severe COVID-19 infection.在肝功能检测值升高的情况下使用瑞德西韦治疗重症新型冠状病毒肺炎感染。
BMJ Case Rep. 2020 Oct 31;13(10):e239210. doi: 10.1136/bcr-2020-239210.
2
Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial.评估静脉用瑞德西韦治疗成人重症 COVID-19 的疗效和安全性:一项 3 期随机、双盲、安慰剂对照、多中心试验的研究方案。
Trials. 2020 May 24;21(1):422. doi: 10.1186/s13063-020-04352-9.
3
Successful treatment with Remdesivir and corticosteroids in a patient with COVID-19-associated pneumonia: A case report.瑞德西韦和皮质类固醇成功治疗1例新冠肺炎相关肺炎患者:病例报告
Medwave. 2020 Aug 19;20(7):e7998. doi: 10.5867/medwave.2020.07.7998.
4
Liver injury in remdesivir-treated COVID-19 patients.接受瑞德西韦治疗的新冠肺炎患者的肝损伤
Hepatol Int. 2020 Sep;14(5):881-883. doi: 10.1007/s12072-020-10077-3. Epub 2020 Jul 28.
5
Delayed Initiation of Remdesivir in a COVID-19-Positive Patient.瑞德西韦治疗 COVID-19 阳性患者的时机延误。
Pharmacotherapy. 2020 Jun;40(6):592-598. doi: 10.1002/phar.2403. Epub 2020 May 20.
6
Tocilizumab and Remdesivir in a Pregnant Patient With Coronavirus Disease 2019 (COVID-19).托珠单抗和瑞德西韦联合治疗 COVID-19 孕妇。
Obstet Gynecol. 2020 Nov;136(5):1025-1029. doi: 10.1097/AOG.0000000000004050.
7
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.瑞德西韦治疗成人重症 COVID-19 的随机、双盲、安慰剂对照、多中心临床试验。
Lancet. 2020 May 16;395(10236):1569-1578. doi: 10.1016/S0140-6736(20)31022-9. Epub 2020 Apr 29.
8
Remdesivir, a remedy or a ripple in severe COVID-19?瑞德西韦,治疗重症 COVID-19 的良药还是涟漪?
Expert Opin Investig Drugs. 2020 Nov;29(11):1195-1198. doi: 10.1080/13543784.2020.1821645. Epub 2020 Sep 20.
9
Probable Molecular Mechanism of Remdesivir for the Treatment of COVID-19: Need to Know More.瑞德西韦治疗 COVID-19 的可能分子机制:需要了解更多。
Arch Med Res. 2020 Aug;51(6):585-586. doi: 10.1016/j.arcmed.2020.05.001. Epub 2020 May 12.
10
[COVID-19 trials: surfing between expectations and illusions, looking forward to evidence].[新冠病毒疾病试验:在期望与幻想之间徘徊,期待证据]
G Ital Cardiol (Rome). 2020 Jul;21(7):479-482. doi: 10.1714/3386.33632.

引用本文的文献

1
Adverse Drug Events Associated With Remdesivir in Real-World Hospitalized Patients With COVID-19, Including Vulnerable Populations: A Retrospective Multicenter Study.真实世界中 COVID-19 住院患者(包括弱势群体)应用瑞德西韦的药物不良反应:一项回顾性多中心研究。
J Korean Med Sci. 2023 Nov 13;38(44):e346. doi: 10.3346/jkms.2023.38.e346.
2
Impact of Liver Functions by Repurposed Drugs for COVID-19 Treatment.用于治疗新冠病毒病的 repurposed 药物对肝功能的影响
J Clin Transl Hepatol. 2022 Aug 28;10(4):748-756. doi: 10.14218/JCTH.2021.00368. Epub 2022 Jan 4.
3
Remdesivir use and risks of acute kidney injury and acute liver injury among patients hospitalised with COVID-19: a self-controlled case series study.瑞德西韦在 COVID-19 住院患者中的使用与急性肾损伤和急性肝损伤的风险:一项自身对照病例系列研究。
Aliment Pharmacol Ther. 2022 Jul;56(1):121-130. doi: 10.1111/apt.16894. Epub 2022 Mar 22.

本文引用的文献

1
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.瑞德西韦对比标准治疗对 11 天内中症 COVID-19 患者临床状态的影响:一项随机临床试验。
JAMA. 2020 Sep 15;324(11):1048-1057. doi: 10.1001/jama.2020.16349.
2
Abnormal Liver Function Tests in Patients With COVID-19: Relevance and Potential Pathogenesis.新型冠状病毒肺炎患者的肝功能异常检查:相关性及潜在发病机制
Hepatology. 2020 Nov;72(5):1864-1872. doi: 10.1002/hep.31480. Epub 2020 Oct 20.
3
Drug-induced Liver Injury in a Patient With Coronavirus Disease 2019: Potential Interaction of Remdesivir With P-Glycoprotein Inhibitors.新型冠状病毒疾病 2019 患者的药物性肝损伤:瑞德西韦与 P-糖蛋白抑制剂的潜在相互作用。
Clin Infect Dis. 2021 Apr 8;72(7):1256-1258. doi: 10.1093/cid/ciaa883.
4
Drug-Induced Liver Injury and COVID-19 Infection: The Rules Remain the Same.药物性肝损伤与新型冠状病毒肺炎感染:规则依旧相同。
Drug Saf. 2020 Jul;43(7):615-617. doi: 10.1007/s40264-020-00954-z.
5
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.瑞德西韦治疗重症 COVID-19 患者的 5 天与 10 天疗程比较
N Engl J Med. 2020 Nov 5;383(19):1827-1837. doi: 10.1056/NEJMoa2015301. Epub 2020 May 27.
6
Remdesivir for the Treatment of Covid-19 - Final Report.瑞德西韦治疗 COVID-19 的疗效 - 最终报告。
N Engl J Med. 2020 Nov 5;383(19):1813-1826. doi: 10.1056/NEJMoa2007764. Epub 2020 Oct 8.
7
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19.美国传染病学会关于2019冠状病毒病患者治疗与管理的指南
Clin Infect Dis. 2020 Apr 27. doi: 10.1093/cid/ciaa478.
8
Compassionate Use of Remdesivir for Patients with Severe Covid-19.瑞德西韦在治疗重症 COVID-19 患者中的同情使用。
N Engl J Med. 2020 Jun 11;382(24):2327-2336. doi: 10.1056/NEJMoa2007016. Epub 2020 Apr 10.
9
Liver injury in COVID-19: management and challenges.新型冠状病毒肺炎中的肝损伤:管理与挑战
Lancet Gastroenterol Hepatol. 2020 May;5(5):428-430. doi: 10.1016/S2468-1253(20)30057-1. Epub 2020 Mar 4.
10
Clinical Characteristics of Coronavirus Disease 2019 in China.《中国 2019 年冠状病毒病临床特征》
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.

在肝功能检测值升高的情况下使用瑞德西韦治疗重症新型冠状病毒肺炎感染。

Use of remdesivir in the presence of elevated LFTs for the treatment of severe COVID-19 infection.

作者信息

Sabers Andrew J, Williams Amber L, Farley T Michael

机构信息

Pharmacy Practice and Science, University of Iowa College of Pharmacy, Iowa City, Iowa, USA.

Pharmacy Practice and Science, University of Iowa College of Pharmacy, Iowa City, Iowa, USA

出版信息

BMJ Case Rep. 2020 Oct 31;13(10):e239210. doi: 10.1136/bcr-2020-239210.

DOI:10.1136/bcr-2020-239210
PMID:33130588
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10577715/
Abstract

An 82-year-old man with an extensive medical history presented to the emergency room with complaints of generalised weakness and cough. He tested positive for COVID-19 10 days prior to presenting to the emergency room. Although his symptoms started a week prior to diagnosis, his weakness increased, warranting emergency response. A comprehensive metabolic panel was drawn from the patient on admission, indicating markedly high liver function tests (LFTs) ≥20 times above the upper limit of normal. On day 1 of admission, the decision was still made to start remdesivir (5-day course) due to decompensated acute respiratory failure as well as dexamethasone. The patient's LFTs significantly improved throughout his hospital stay. The patient made a full recovery and was discharged on day 10 of hospitalisation.

摘要

一名有广泛病史的82岁男性因全身乏力和咳嗽前往急诊室就诊。他在前往急诊室就诊前10天新冠病毒检测呈阳性。尽管他的症状在诊断前一周就已出现,但乏力症状加重,需要紧急处理。入院时对患者进行了全面代谢检查,结果显示肝功能检查(LFTs)显著升高,比正常上限高出≥20倍。入院第1天,由于急性呼吸衰竭失代偿以及考虑使用地塞米松,仍决定开始使用瑞德西韦(疗程为5天)。患者住院期间肝功能检查结果显著改善。患者完全康复,于住院第10天出院。